COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
Schachna
L
L
Ryan
P F
PF
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001315:Australia; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D017277:Drug Approval; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects*; D007783:Lactones / Q000494:pharmacology; D008565:Membrane Proteins; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib